Detection of Recurrent Cancer by Biochemical Testing in High Risk Prostate Cancer Patients Treated with Thailand Standard Protocol
Recurrent Cancer by Biochemical Testing in High Risk Prostate Cancer Patients
Keywords:
high risk prostate cancer patient, recurrence, biochemical test, radiation therapy, androgen deprivation therapyAbstract
Intensity Modulated Radiation (IMRT) is a common treatment for high risk prostate cancer patients who did not eligible for surgery. The objective was to evaluate biochemical recurrence (BCR) and related factors in high risk prostate cancer patients who received completed IMRT and androgen-deprivation therapy (ADT) for two years by Thailand standard protocol. A retrospective cohort study, in which data collection and analysis of medical records were collected in high risk prostate cancer patients receiving IMRT and ADT at Naresuan University Hospital from January 1, 2013 to December 30, 2021. Six patients out of total 77 patients (7.8%) were reported BCR. BCR-free survival at 24, 36, 48 and 60 months after completed IMRT was 97.2%, 94.1% 81.3% and 60.97% respectively. On log rank test, for subgroup which the pre-radiation PSA level ≥ 20 ng/mL (p = 0.038), PSA density ≥ 0.5 ng/mL/mL and pathologic Gleason score ≥ 8 were statistically significant factors causing BCR. In this study, the significant factors associated with BCR are pre-radiation PSA > 20 ng/mL, pre-radiation PSA density > 0.5 ng/mL/mL and GS ≥ 8. Thus, multimodality of treatments should be encouraged with multidisciplinary team.
References
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17-48.
International Agency for Research on Cancer (WHO). Thailand cancer fact sheets 2020. [Internet]. 2021 March [cited 2023 March 2]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-74.
Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology 2007;70(5):931-5.
National Comprehensive Cancer Network. Prostate cancer (Version1.2022) [Internet]. 2021 April [cited 2021 April 11]. Available from: https://www.nccn.org/professinals/physician_gls/pdf/ prostate.pdf
Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 2002;95(11):2302-7.
Manorom D, Pripatnanont C, Siraprapasiri P, editors. Guideline for screening diagnosis and management of prostate cancer. Bangkok, Thailand: Kosit Press Company Limited; 2017.
Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-74. doi: 10.1016/j.ijrobp.2006.04.029
Saad A, Goldstein J, Lawrence YR, Spieler B, Leibowitz-Amit R, Berger R, et al. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation? Radiat Oncol 2017;12(1):5. doi: 10.1186/s13014-016-0743-2
Gunnarsson O, Schelin S, Brudin L, Carlsson S, Damber J-E. Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy. Scand J Urol 2019;53(2–3):102–8.
Wang Z, Ni Y, Chen J, Sun G, Zhang X, Zhao J et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World J Surg Oncol 2020;18(1):42. doi: 10.1186/s12957-020-01824-9
Leal-García M, Canto P, Cárdenas-Cárdenas E, Feria-Bernal G, García-García E, Méndez JP. Overweight and obesity in men with prostate cancer do not constitute risk factors for biochemical recurrence. Aging Male 2020;23(5):1283-8.
Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl 2018;20(6):551-4.
Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002;168(5):2001–5.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Buddhchinaraj Phisanulok Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
